Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 7/20 | 0.61 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.61 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.61 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.59 |
| ▸ | TDO2 | P48775 | 2/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | AKT1 | P31749 | 2/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
| ▸ | CDC7 | O00311 | 1/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.49 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.49 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5007325 | 0.92 | PRKCZ (0.70) | CYP11B2CYP11B1CYP19A1CYP17A1PRKCZ | |
| SCHEMBL18891280 | 0.90 | CYP11B1 (0.69) | CYP11B2CYP11B1CYP19A1CYP17A1PRKCZ | |
| SCHEMBL444504 | 0.88 | PRKCZ (0.63) | CYP11B2CYP11B1CYP19A1CYP17A1PRKCZ | |
| SCHEMBL22215497 | 0.87 | CYP11B2 (0.56) | CYP11B2CYP11B1CYP19A1CYP17A1PRKCZ | |
| SCHEMBL18556708 | 0.86 | CYP11B1 (0.69) | CYP11B2CYP11B1CYP19A1CYP17A1PRKCZ | |
| SCHEMBL26565936 | 0.85 | NOTUM (0.68) | CYP11B2CYP11B1CYP19A1CYP17A1ESR1 | |
| SCHEMBL27895115 | 0.84 | CYP11B2 (0.85) | CYP11B2CYP11B1CYP19A1CYP17A1 | |
| SCHEMBL26565897 | 0.84 | CYP11B2 (0.85) | CYP11B2CYP11B1CYP19A1CYP17A1 | |
| SCHEMBL22215534 | 0.84 | PRKCZ (0.56) | CYP11B2CYP11B1CYP19A1CYP17A1PRKCZ | |
| SCHEMBL17229031 | 0.83 | TDO2 (0.57) | CYP11B2CYP11B1CYP19A1CYP17A1PRKCZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107074958-A | Anti- PD L1 for treating tumour are combined | 博笛生物科技有限公司 | 2017-08-18 | — | — | CN | disclosed |
| CN-107074959-A | Anti- PD L1 conjugates for treating tumour | 博笛生物科技有限公司 | 2017-08-18 | — | — | CN | disclosed |
| CN-106943596-A | anti-CD 20 combination for use in the treatment of tumors | 博笛生物科技（北京）有限公司 | 2017-07-14 | — | — | CN | disclosed |
| CN-106943598-A | anti-HER 2 combination for treating tumors | 博笛生物科技（北京）有限公司 | 2017-07-14 | — | — | CN | disclosed |
| CN-106535938-A | Combination therapeutic compositions and combination therapeutic methods for treating cancer | 上海博笛生物科技有限公司 | 2017-03-22 | — | — | CN | disclosed |
| US-6933306-B2 | Hydroxamic and carboxylic acid derivatives | DARWIN DISCOVERY LTD. (GB) | 2005-08-23 | — | — | US | disclosed |
| US-20030092727-A1 | Hydroxamic and carboxylic acid derivatives | HANNAH DUNCAN ROBERT (GB) | 2003-05-15 | — | — | US | disclosed |
| EP-1292576-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | Darwin Discovery Limited (GB) | 2003-03-19 | — | — | EP | disclosed |
| US-6506773-B2 | For therapy of cancer; inflammation; an autoimmune, infectious or ocular disease; or age-related macular degeneration | DARWIN DISCOVERY LTD. (GB) | 2003-01-14 | — | — | US | disclosed |
| US-20020022635-A1 | Hydroxamic and carboxylic acid derivatives | DARWIN DISCOVERY LIMITED (GB) | 2002-02-21 | — | — | US | disclosed |
| WO-2001087844-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | DARWIN DISCOVERY LIMITED (GB) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092727-A1 | Hydroxamic and carboxylic acid derivatives | UACA, HCAR2, HCAR1 | CYP11B2 1816/4885CYP11B1 1849/4885CYP19A1 2074/4885 |
| US-20020022635-A1 | Hydroxamic and carboxylic acid derivatives | HCAR1, HCAR2, HCAR3 | CYP11B2 383/4885CYP11B1 521/4885CYP19A1 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.